Eyestem Research announced positive results from its phase 1 trial ( NCT06394232) evaluating its investigational drug product ...

Eyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy ...

Eyestem Research, a Bangalore-based cell therapy company, is pleased to announce significant vision improvement in Phase 1 trials of its investigational drug, Eyecyte-RPEtm, in patients with ...

Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs of disease reversal observed in some patients. Dr Jogin Desai, Founder ...

A novel DIPN method enhances GA segmentation by integrating ConvLSTM, projection attention, adaptive pooling, and contrastive ...

vitrectomy in retinal detachment surgery ... discusses the importance of geographic atrophy awareness and the role of direct consumer advertising for treatments. In this video, Michael Stewart ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... characterised by the loss of photoreceptors and retinal pigment epithelial (RPE) cells in the central ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Selective breeding has worked wonders in transforming cats into the creatures we adore today, but it’s not all about looks.